48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial

Overview of attention for article published in BMC Infectious Diseases, May 2014

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 46,824 followers.

Dolutegravir+ABC+3TC versus TDF+FTC+EFV. Mayor turn-over óseo con Tenofovir. http://t.co/4TCZB84Abu http://t.co/jOEKxQVUpQ

Reply Repost Favourite

Dolutegravir+Abacavir/3TC+TDF+EFV. Mayor actividad del turn-over óseo con Tenofovir. http://t.co/4TCZB84Abu http://t.co/jOEKxQVUpQ

Reply Repost Favourite